BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that it has entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3 million of shares of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit. The entire transaction has been priced at the market under ...

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is advancing its first-in-class PP2A inhibitor, LB-100, and will present at the Spartan Capital Investor Conference 2025, highlighting its potential in cancer therapy [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new avenues for cancer drug development [3]. - The lead compound, LB-100, has shown to be well-tolerated in cancer patients and has the potential to enhance the effectiveness of existing chemotherapies and immunotherapies [3][4]. Product Development - LB-100 is part of a novel approach in cancer biology known as activation lethality, which is aimed at creating a new treatment paradigm [4]. - Clinical trials for LB-100 are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [4].

Core Insights - LIXTE Biotechnology Holdings, Inc. is focused on advancing its lead compound LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), while pursuing strategic acquisitions in oncology [1][2][4] Group 1: Clinical Execution - The company is committed to the continued advancement of LB-100 across prioritized tumor settings, supported by growing clinical and preclinical evidence [8] - Ongoing proof-of-concept clinical trials for LB-100 are in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [5] Group 2: Strategic Expansion - LIXTE is entering Q4 2025 with clear operational goals and a disciplined approach to strategic expansion, focusing on high-need cancer indications [2][3] - The company is in advanced negotiations for potential acquisitions of complementary oncology assets to enhance its pipeline and accelerate development [2][8] Group 3: Operational Readiness - The company is undertaking initiatives in quality, chemistry, manufacturing, and regulatory alignment to support efficient study conduct and potential integration of acquired programs [8]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is diversifying its treasury by purchasing cryptocurrencies, specifically 10.5 Bitcoin and 300 Ethereum, totaling approximately $2.6 million, which now constitutes about 43.6% of its treasury holdings [2][3]. Group 1: Cryptocurrency Strategy - The company has received approval from its Board of Directors to increase its cryptocurrency allocation to up to 50% of its treasury [2]. - The addition of Bitcoin and Ethereum is part of a strategy to build a balanced digital asset portfolio that complements cash holdings [3]. - The company aims to enhance its adaptability and long-term growth in the digital economy through this diversification [3]. Group 2: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound, LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [4][5]. - The company is engaged in pioneering research in cancer biology, specifically in the area of activation lethality, and is currently conducting proof-of-concept clinical trials for various cancer types [5].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has relocated its corporate headquarters to Boca Raton, Florida, and appointed new board members and a Chief Financial Officer to strengthen its operations and strategic direction [1][2][4]. Company Developments - The company has appointed Lourdes Felix and Guy Primus to its Board of Directors, while Peter Stazzone has been named Chief Financial Officer [1][2]. - Stazzone brings over 20 years of financial management experience, having served as CFO for several companies, and is expected to guide corporate transformations and financial processes at LIXTE [5]. - Felix will chair LIXTE's Audit Committee, bringing over 30 years of experience in management and corporate finance [6]. - Primus has a 30-year track record in technology-driven organizations and has held senior positions at notable companies like Starbucks and Microsoft [7]. Strategic Implications - The relocation to Florida is aimed at enhancing operational efficiency in a business-friendly environment, which is expected to reduce costs and create long-term value for shareholders [4]. - The new leadership team is anticipated to evaluate new business opportunities and strengthen the company's mission in developing cancer therapies [3]. Product Focus - LIXTE is focused on developing a new class of cancer therapy, specifically its lead compound LB-100, which has shown potential in enhancing chemotherapy and immunotherapy [8][9]. - LB-100 is part of a pioneering effort in cancer biology, with ongoing proof-of-concept clinical trials for various cancer types [9].

Core Insights - LIXTE Biotechnology Holdings, Inc. has completed two financings, raising a total of $6.5 million, which has allowed the company to regain compliance for continued listing on Nasdaq [1][3] - The company has announced management changes, including the appointment of Geordan Pursglove as Chairman and CEO, and the addition of two new independent board members [1][3] - Recent findings published in the journal Nature validate LIXTE's ongoing clinical trials with its lead compound, LB-100, for treating ovarian and colorectal cancer [1][2][3] Financing Activities - LIXTE completed a private placement with accredited investors, raising approximately $5 million, and a registered direct offering, raising approximately $1.5 million [3] - The proceeds from these financings will be used for general corporate purposes and working capital [3] Management Changes - Geordan Pursglove was appointed as Chairman and CEO in June 2025, succeeding Bas van der Baan, who became President and Chief Scientific Officer [3] - Jason Sawyer and Michael Holloway, MD, joined LIXTE's Board as independent directors in July 2025 [3] Scientific Developments - The publication in Nature highlights that patients with tumors having inactivating mutations in PPP2R1A showed significantly better overall survival when treated with immune checkpoint blockade therapy [2][3] - LIXTE has initiated a new pre-clinical study in collaboration with the Netherlands Cancer Institute to test the efficacy of LB-100 on "initiated" cells carrying mutations found in cancer cells [3] Product Pipeline - LIXTE's lead compound, LB-100, is a first-in-class PP2A inhibitor that is well-tolerated in cancer patients and has the potential to enhance chemotherapy and immunotherapy [4][5] - Clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma [5]

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has regained compliance with Nasdaq's Listing Rule 5550(b)(1) after successfully closing a $5.0 million placement and a $1.5 million registered direct offering, ensuring its continued listing on the Nasdaq Capital Market [1][2]. Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, particularly targeting new areas in cancer drug development [3][4]. - The company's lead clinical compound, LB-100, is a first-in-class PP2A inhibitor that has shown promise in enhancing chemotherapies and immunotherapies for cancer patients [3][4]. Financial Health - The recent capital raises of $5.0 million and $1.5 million have bolstered the company's financial position, allowing it to meet the minimum equity requirement of $2.5 million for Nasdaq compliance [1][2]. - CEO Geordan Pursglove emphasized the company's commitment to maintaining its Nasdaq listing and improving its financial health while pursuing clinical trials for various cancers [3]. Clinical Development - LIXTE is currently conducting proof-of-concept clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma [4]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [4].

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering, raising approximately $1.5 million through the sale of shares of Common Stock and Pre-Funded Warrants [1][3]. Group 1: Offering Details - The offering included the sale of 974,026 shares of Common Stock or Pre-Funded Warrants, with a public offering price of $1.54 per share [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. - The gross proceeds from the transaction amounted to approximately $1.5 million, and the transaction closed on July 8, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are expected to be used for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead clinical compound, LB-100, which has shown potential in enhancing chemotherapies and immunotherapies [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, and proof-of-concept clinical trials are currently underway for various cancer types [7].

Core Viewpoint - LIXTE Biotechnology Holdings, Inc. is initiating a pre-clinical study in collaboration with the Netherlands Cancer Institute to explore the potential of its compound LB-100 in eliminating "initiated" cells that carry mutations associated with cancer [1][2]. Group 1: Study Details - The new study will focus on whether LB-100 can eliminate "initiated" cells with a mutant RAS oncogene in animal models, which could significantly reduce the risk of developing various cancers as individuals age [3]. - The study is part of LIXTE's broader strategy to enhance cancer prevention efforts alongside ongoing clinical trials for ovarian and colorectal cancers [2]. Group 2: Leadership and Expertise - The study will be led by Dr. René Bernards, a prominent figure in molecular carcinogenesis and a member of LIXTE's Board of Directors, highlighting the expertise behind the research [4]. Group 3: Company Background - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 showing promise in terms of patient tolerance and low toxicity during Phase 1 clinical trials [5][6]. - LB-100 is positioned as a first-in-class PP2A inhibitor, with potential applications in enhancing chemotherapies and immunotherapies for cancer patients [5].